1-(N,N-dimethylsulfamoyl)-4-methylimidazole | 151161-77-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(N,N-dimethylsulfamoyl)-4-methylimidazole
• 英文别名: N,N-4-trimethyl-1H-imidazole-1-sulfonamide；4-methylimidazole-1-sulfonic acid dimethylamide；4-methyl-1-dimethylsulfamoylimidazole；N,N,4-trimethyl-1H-Imidazole-1-sulfonamide；N,N,4-trimethylimidazole-1-sulfonamide
• CAS: 151161-77-2
• 化学式: C₆H₁₁N₃O₂S
• 分子量: 189.238
• InChiKey: IHIUXCVWNRHBDG-UHFFFAOYSA-N

物化性质

• 熔点：
  78-82 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• 沸点：
  323.8±35.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(N,N-dimethylsulfamoyl)-4-methylimidazole 在 sodium tetrahydroborate 、 正丁基锂 作用下， 以 四氢呋喃 、 甲醇 、 环己烷 为溶剂， 反应 3.5h， 生成 2-(hydroxymethyl)-N,N,4-trimethylimidazole-1-sulfonamide
  参考文献：
  名称：

  [EN] PYRAZOLYL QUINAZOLINE KINASE INHIBITORS
  [FR] INHIBITEURS DE PYRAZOLYL-QUINAZOLINE KINASE

  摘要：

  这项发明涉及新的喹喔啉衍生物化合物，包括含有该化合物的药物组合物，制备该化合物的方法以及利用该化合物治疗疾病，例如癌症。

  公开号：

  WO2011135376A1
• 作为产物：
  描述：

  4-甲基咪唑 、 二甲胺基磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-(N,N-dimethylsulfamoyl)-4-methylimidazole
  参考文献：
  名称：

  （苯）咪唑的区域选择性N-甲基化的发展提供了更受阻的异构体

  摘要：

  已经开发了一种高效且高度区域选择性的（NH）-（苯并）咪唑的N-甲基化，其提供在空间上更受阻，不太稳定并且通常为较小的区域异构体。该方法涉及非常温和的反应条件，并能耐受各种官能团。

  DOI：

  10.1021/jo401978b

文献信息

• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors
  申请人：Allergan Sales, Inc.

  公开号：US20020156076A1

  公开（公告）日：2002-10-24

  Compounds having adrenergic activity which are a selective agonists for one or both of the &agr; 2B and &agr; 2c adrenoceptor receptor subtypes in preference to the &agr; 2A adrenoceptor receptor subtype; the active compound being selected from the group consisting of compounds having the formula 1 wherein the dotted lines represent optional bonds provided that two double bonds may not share a common carbon atom; R is H or lower alkyl; X is S or C(H)R 1 , wherein R 1 is H or lower alkyl, but R 1 is absent when the bond between X and the ring represented by 2 is a double bond; Y is O, N, S, (CR 1 2 ) y , wherein y is an integer of from 1 to 3, —CH═CH— or —Y 1 CH 2 —, wherein Y 1 is O, N or S; x is an integer of 1 or 2, wherein x is 1 when R 2 , R 3 or R 4 is bound to an unsaturated carbon atom and x is 2 when R 2 , R 3 or R 4 is bonded to a saturated carbon atom; R 2 is H, lower alkyl, halogen, hydroxy, lower alkoxy, lower alkenyl, acyl or lower alkynyl, or, when attached to a saturated carbon atom, R 2 may be oxo; R 3 and R 4 are, each, H, lower alkyl, halogen, lower alkenyl, acyl, lower alkynyl, aryl, heteroaryl, or sub stituted aryl or heteroaryl, wherein said substituent is halogen, lower alkyl, lower alkoxy, lower alkenyl, acyl, lower alkynyl, nitro, cyano, trifluoromethyl, hydroxy, or phenyl or, together, are —(C(R 2 )x)z—; —Y 1 (C(R 2 )x)z′—; —Y 1 (C(R 2 )x)y Y 1 —; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—; —(C(R 2 )x)—Y 1 —(C(R 2 )x)—(C(R 2 )x)— and —Y 1 —(C(R 2 )x)—Y 1 —(C(R 2 )x)— wherein z is an integer of from 3 to 5, z′ is an integer of from 2 to 4 and x and y are as defined above, and further either end of each of these divalent moieties may attach at either R3 or R4 to form a condensed ring structure and the rings formed may be totally unsaturated, partially unsaturated, or totally saturated; and being useful for treating muscle spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases, memory and cognition deficits, psychoses including manic disorders and anxiety, hypertension, cardiac ischemia, congestive heart failure, and nasal congestion without sedating or cardiovascular side effects.

  具有肾上腺素活性的化合物，是选择性激动剂，优先作用于α2B和α2C肾上腺素受体亚型中的一个或两个，而不是α2A肾上腺素受体亚型；所述活性化合物从以下化合物组中选择，其具有下列式1的化合物，其中虚线代表可选键，但两个双键不能共用一个碳原子；R为H或较低的烷基；X为S或C(H)R1，其中R1为H或较低的烷基，但当X与由2表示的环之间的键为双键时，R1不存在；Y为O、N、S、(CR12)y，其中y为1至3的整数，—CH2CH—或—Y1CH2—，其中Y1为O、N或S；x为1或2的整数，当R2、R3或R4与不饱和碳原子结合时，x为1，当R2、R3或R4与饱和碳原子结合时，x为2；R2为H、较低的烷基、卤素、羟基、较低的烷氧基、较低的烯基、酰基或较低的炔基，或者当连接到饱和碳原子时，R2可能为酮基；R3和R4分别为H、较低的烷基、卤素、较低的烯基、酰基、较低的炔基、芳基、杂环芳基或取代的芳基或杂环芳基，其中所述取代基为卤素、较低的烷基、较低的烷氧基、较低的烯基、酰基、较低的炔基、硝基、氰基、三氟甲基、羟基或苯基，或者共同为—(C(R2)x)z—；—Y1(C(R2)x)z′—；—Y1(C(R2)x)y Y1—；—(C(R2)x)—Y1—(C(R2)x)—；—(C(R2)x)—Y1—(C(R2)x)—(C(R2)x)—和—Y1—(C(R2)x)—Y1—(C(R2)x)—其中z为3至5的整数，z′为2至4的整数，x和y如上所定义，而且这些二价基团的每一端都可以连接到R3或R4中的任一端，形成一个紧凑的环结构，所形成的环可以是完全不饱和的、部分不饱和的或完全饱和的；并且适用于治疗肌肉痉挛，包括过度活跃的小便、腹泻、利尿、戒断综合征、包括神经病理性疼痛、神经退行性疾病、记忆和认知缺陷、精神病，包括躁狂障碍和焦虑、高血压、心肌缺血、充血性心力衰竭和鼻塞，无镇静或心血管副作用。
• Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
  申请人：ALLERGAN SALES, INC.

  公开号：US20030023098A1

  公开（公告）日：2003-01-30

  Methods and compounds for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects. Also included are methods of making and using such compounds.

  用于治疗疼痛、特别是慢性疼痛、青光眼或高眼压的方法和化合物，具有减少心血管或镇静副作用。还包括制备和使用这些化合物的方法。
• A Short and Efficient Synthesis of the Selective H4 Receptor Agonist 4- Methylhistamine
  作者：Mirko Rivara、Valentina Zuliani、Pier Plazzi、Fabrizio Bordi

  DOI：10.2174/157017809787003223

  日期：2009.1.1

  An efficient synthesis of the selective H4 receptor agonist 4-methylhistamine is described. This approach can be used to prepare, without purification steps and in high yield, significant quantities of the product, useful as pharmacological tool to investigate the physiological roles of the histamine H4 receptor.

  描述了一种高效合成选择性H4受体激动剂4-甲基组胺的方法。该方法可以在没有纯化步骤的情况下，以高产率制备大量该产品，作为药理工具用于研究组胺H4受体的生理作用。
• Imidazole-based compounds, compositions comprising them and methods of their use
  申请人：Augeri J. David

  公开号：US20070208063A1

  公开（公告）日：2007-09-06

  Imidazole-based compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of inflammatory and autoimmune diseases and disorders are disclosed. Particular compounds are of formula I:

  基于咪唑的化合物、包含它们的组合物以及它们用于治疗、预防和管理炎症性和自身免疫性疾病和紊乱的方法被披露。特定的化合物具有如下式I：
• S1P LYASE INHIBITORS FOR THE TREATMENT OF CEREBRAL MALARIA
  申请人：Brown Philip Manton

  公开号：US20100113530A1

  公开（公告）日：2010-05-06

  Methods and compositions for treating, managing, and/or preventing cerebral malaria are disclosed.

  揭示了用于治疗、管理和/或预防脑疟疾的方法和组合物。